Taejoon Pharmaceutical Co., Ltd.

DelveInsight's 'Mydriasis Pipeline Insight, 2024' report details the global Mydriasis pipeline, featuring 3+ key companies developing 3+ therapies. Insights include clinical trials, mechanism of action, route of administration, and emerging therapies like RYZUMVI, MYDCOMBI, and OMIDRIA. The report covers pre-clinical to marketed phases, highlighting active and inactive projects, collaborations, and market dynamics.